DIACYLGLYCEROL-ACYLTRANSFERASE 2 INHIBITORS Russian patent published in 2020 - IPC C07D401/14 A61K31/506 A61P3/10 A61P3/06 A61P1/16 A61P9/10 A61P7/02 A61P19/04 A61P1/04 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a novel compound of formula I and a pharmaceutically acceptable salt thereof. In formula (I)

(I)

D¹ is CH; and D² is N or CH; R¹ is H or (C₁-C₂) alkyl, optionally substituted with one or two substitutes, each of which is independently selected from fluorine; R² denotes H or fluorine; R³ is , or ; R⁴ is H, cyano or (C₁-C₄) alkyl optionally substituted with one substitute, each of which is independently selected from -OH and -S(O)₂R⁶; R⁵ denotes H or -OH; and R⁶ is (C₁-C₄) alkyl. Preferred compound is compound

(I')

of formula (I'). Said compound can be obtained in form of a crystalline form I, having powder X-ray powder (PXRD) peaks at CuKα radiation at 2-theta (°) angle of 5.3, 7.7, 15.4, or in the form of crystalline form II, having X-ray powder pattern (PXRD) peaks at radiation of CuKα at angle 2-theta (°) 6.5, 9.3, 13.6.

EFFECT: compounds inhibit the activity of diacylglycerol acyltransferase 2 (DGAT2) and can be used for treating non-alcoholic fatty dystrophy, non-alcoholic steatohepatitis, hyperlipidemia, diabetes and other diseases associated with DGAT2 activity.

14 cl, 4 dwg, 4 tbl, 8 ex